Skip to content

Cognitive control training for major depression: application, evaluation and augmentation.

Can concurrent transcranial direct current stimulation augment the antidepressant efficacy of cognitive control training for major depression?

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12613000050752
Enrollment
27
Registered
2013-01-15
Start date
2012-07-25
Completion date
2013-06-28
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Many depressed individuals fail to respond to available pharmacological and psychological therapies and there is a significant need to develop novel antidepressant treatment approaches. Traditionally, both research into and treatment approaches for depression have focused on the emotional disturbance associated with this illness. However, depression also disrupts cognitive processing. There is now considerable evidence indicating that the cognitive and emotional symptoms of depression interact with each other (e.g. causing an individual to remember more negative memories, or to pay more attention to negative thoughts and stimuli), and these interactions directly contribute to the length and severity of depressive episodes. Recently it has been suggested that targeting the cognitive symptoms of depression may also help to improve emotional dysfunction. One way that this could be achieved via cognitive control training (CCT). CCT simply involves a small number of thinking activities that an individual repeatedly practices to improve their ability to sustain and focus their attention and to self-direct their thought processes. The cognitive processes that CCT aims to enhance are largely subsumed by a frontal region of the brain called the dorsolateral prefrontal cortex. Research has shown that a mild form of brain stimulation called transcranial direct current stimulation (tDCS) administered to this brain region can enhance cognitive processing. As such, tDCS may be a useful means of augmenting the efficacy of CCT for depression.

Interventions

Participants engage in five treatment sessions on consequent week days. Each session comprises cognitive training coupled with active or sham transcranial direct current stimulation (tDCS). Specifically, participants are randomised to one of the following intervention conditions: a) cognitive control training + anodal tDCS (2mA) b) cognitive control training + sham tDCS c) peripheral vision training + anodal tDCS (2mA) Cognitive control training comprises a set of computerised thinking tasks

Participants engage in five treatment sessions on consequent week days. Each session comprises cognitive training coupled with active or sham transcranial direct current stimulation (tDCS). Specifically, participants are randomised to one of the following intervention conditions: a) cognitive control training + anodal tDCS (2mA) b) cognitive control training + sham tDCS c) peripheral vision training + anodal tDCS (2mA) Cognitive control training comprises a set of computerised thinking tasks designed to engage the dorsolateral prefrontal cortex region of the brain. The peripheral vision training comprises a set of computerised thinking tasks designed to engage the visual cortex to a great degree than the dorsolateral prefrontal cortex. Both types of training will be administered concurrently with active/sham tDCS throughout five 24-minute treatment sessions.

Sponsors

Monash University
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Primary purpose
Treatment

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Are voluntary and competent to consent, 2. Are currently in the midst of a DSM-IV defined Major Depressive Episode.

Exclusion criteria

1. Have a DSM-IV defined history of bipolar disorder, psychotic illness, obsessive compulsive disorder or substance abuse or dependence in the last 6-months, 2. Have a history of traumatic brain injury or neurologic illness, 3. Are currently taking carbamazepine or benzodiazepines, 4. Are currently pregnant or lactating.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026